181 related articles for article (PubMed ID: 12222872)
1. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.
Roberts M; Dickson G
Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872
[TBL] [Abstract][Full Text] [Related]
2. Progress toward gene therapy of Duchenne muscular dystrophy.
Hartigan-O'Connor D; Chamberlain JS
Semin Neurol; 1999; 19(3):323-32. PubMed ID: 12194388
[TBL] [Abstract][Full Text] [Related]
3. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).
Athanasopoulos T; Graham IR; Foster H; Dickson G
Gene Ther; 2004 Oct; 11 Suppl 1():S109-21. PubMed ID: 15454965
[TBL] [Abstract][Full Text] [Related]
4. Full-length dystrophin gene transfer to the mdx mouse in utero.
Reay DP; Bilbao R; Koppanati BM; Cai L; O'Day TL; Jiang Z; Zheng H; Watchko JF; Clemens PR
Gene Ther; 2008 Apr; 15(7):531-6. PubMed ID: 18273052
[TBL] [Abstract][Full Text] [Related]
5. Transduction of myogenic cells by retargeted dual high-capacity hybrid viral vectors: robust dystrophin synthesis in duchenne muscular dystrophy muscle cells.
Gonçalves MA; Holkers M; Cudré-Mauroux C; van Nierop GP; Knaän-Shanzer S; van der Velde I; Valerio D; de Vries AA
Mol Ther; 2006 May; 13(5):976-86. PubMed ID: 16443396
[TBL] [Abstract][Full Text] [Related]
6. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
Lai Y; Li D; Yue Y; Duan D
Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
[TBL] [Abstract][Full Text] [Related]
7. Gene therapy for duchenne muscular dystrophy: expectations and challenges.
Rodino-Klapac LR; Chicoine LG; Kaspar BK; Mendell JR
Arch Neurol; 2007 Sep; 64(9):1236-41. PubMed ID: 17846262
[TBL] [Abstract][Full Text] [Related]
8. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
Duan D
Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
[TBL] [Abstract][Full Text] [Related]
9. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype.
Yoshimura M; Sakamoto M; Ikemoto M; Mochizuki Y; Yuasa K; Miyagoe-Suzuki Y; Takeda S
Mol Ther; 2004 Nov; 10(5):821-8. PubMed ID: 15509500
[TBL] [Abstract][Full Text] [Related]
10. [Adeno-associated virus vector carrying human minidystrophin gene SMCKA3999 effectively ameliorates dystrophic pathology in mdx model mice].
Li HH; Zhang SM; Fang SY; Chen CL; Luo YD; Guan Y; Wang DW; Xiao X
Zhonghua Yi Xue Za Zhi; 2003 Sep; 83(17):1513-6. PubMed ID: 14521733
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
12. Gene therapy progress and prospects: Duchenne muscular dystrophy.
Foster K; Foster H; Dickson JG
Gene Ther; 2006 Dec; 13(24):1677-85. PubMed ID: 17066097
[TBL] [Abstract][Full Text] [Related]
13. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors.
Blankinship MJ; Gregorevic P; Chamberlain JS
Mol Ther; 2006 Feb; 13(2):241-9. PubMed ID: 16361117
[TBL] [Abstract][Full Text] [Related]
15. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy for muscle disease.
Miyagoe-Suzuki Y; Takeda S
Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
[TBL] [Abstract][Full Text] [Related]
17. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
[TBL] [Abstract][Full Text] [Related]
18. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
[TBL] [Abstract][Full Text] [Related]
19. Long-term expression of full-length human dystrophin in transgenic mdx mice expressing internally deleted human dystrophins.
Ferrer A; Foster H; Wells KE; Dickson G; Wells DJ
Gene Ther; 2004 Jun; 11(11):884-93. PubMed ID: 14985788
[TBL] [Abstract][Full Text] [Related]
20. Dystrophic phenotype of canine X-linked muscular dystrophy is mitigated by adenovirus-mediated utrophin gene transfer.
Cerletti M; Negri T; Cozzi F; Colpo R; Andreetta F; Croci D; Davies KE; Cornelio F; Pozza O; Karpati G; Gilbert R; Mora M
Gene Ther; 2003 May; 10(9):750-7. PubMed ID: 12704413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]